TMO · 10-Q · 2026Q3 · Full report

Diagnostics Product Momentum

THERMO FISHER SCIENTIFIC INC. · 2026-10-30 · Importance 26 · Surprise 24

Specialty Diagnostics’ organic revenues were flat in the third quarter of 2026. Organic revenue increased in the first nine months, led by the transplant diagnostics and immunodiagnostics businesses. The filing attributes the segment’s reported revenue decline for the nine-month period to the microbiology business divestiture, offset by modest growth across its other businesses.

Key facts

• Thermo Fisher Scientific Inc.’s Specialty Diagnostics organic revenues were flat in the third quarter of 2026; reported segment revenues declined primarily due to the microbiology business divestiture. source
• In the first nine months of 2026, Thermo Fisher Scientific Inc.’s Specialty Diagnostics organic revenues increased, led by transplant diagnostics and immunodiagnostics. source
• In the first nine months of 2026, the impact of Thermo Fisher Scientific Inc.’s microbiology business divestiture on Specialty Diagnostics reported revenue was offset by modest growth across the segment’s other businesses. source
• In the third quarter of 2026, Thermo Fisher Scientific Inc.’s revenue to customers in the diagnostics and healthcare market grew slightly. source
• In the first nine months of 2026, Thermo Fisher Scientific Inc.’s revenues to customers in the diagnostics and healthcare market grew slightly. source